Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02545517
Other study ID # 205214
Secondary ID 2015-000382-31V4
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date October 5, 2015
Est. completion date November 18, 2022

Study information

Verified date January 2022
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

GlaxoSmithKline (GSK) Biologicals' Rabipur vaccine is indicated for active immunization against rabies in individuals of all ages. This includes pre-exposure prophylaxis (PrEP), in both primary series and booster dose, and post exposure prophylaxis.The aim of this extension study is to evaluate the long-term (up to approx.10 years) persistence and to assess the boostability of immune responses in subjects who received a primary series of accelerated or conventional rabies PrEP IM regimen No new subjects were enrolled in this study.


Description:

The protocol was amended to clarify: - Timeframe between each yearly scheduled visit, - Number of additional booster doses a subject may receive depending on the RVNA level reached, - Premature withdrawal from the study - Exclusion criteria on scheduled visits - That only SAEs experienced by subjects who received the booster must be reported - Rewording of the protocol.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 459
Est. completion date November 18, 2022
Est. primary completion date November 18, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: In order to participate in this study, all subjects must meet ALL of the inclusion criteria described. 1. All individuals who were randomized to Conventional Rabies and JE vaccination or to Accelerated Rabies and JE vaccination or to Conventional Rabies groups during the parent study, who received the full PrEP regimen and completed the trial following V49_23 study protocol. 2. Individuals who have voluntarily given written informed consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry. 3. Individuals who can comply with study procedures 4. Males Or Females of non-childbearing potential Or Females of childbearing potential who are using an effective birth control method which they intend to use for at least 6 months after the booster vaccination. This criterion is applicable only for those subjects who receive a booster dose. Prior to receipt of booster vaccination during Ad hoc Clinic Visit, subjects must be evaluated to confirm that they are eligible. If subjects do not meet any of the original inclusion criteria listed above, they should not receive booster dose of rabies vaccine. Exclusion Criteria: Prior to extension study entry, each subject must not have: 1. Completed the parent study V49_23 without receiving the full 3 rabies vaccine doses following the assigned pre-exposure prophylaxis regimen. 2. History of exposure to suspected or confirmed rabid animal. 3. Receipt of rabies immunoglobulins, rabies post exposure prophylaxis following completion of V49_23 study. 4. Hypersensitivity, including allergy, to any component of vaccines, medicinal products or medical equipment whose use is foreseen in this study. 5. Clinical conditions representing a contraindication to intramuscular vaccination and blood draws. 6. Systemic administration of corticosteroids (PO/IV/IM) for more than 14 consecutive days within 90 days prior to informed consent or planning to receive them during the participation to the study. 7. Administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to informed consent or planning to receive them during the participation to the study. 8. Received immunoglobulins or any blood products within 180 days prior to informed consent or planning to receive them during the participation to the study. 9. Study personnel as well as their immediate family or household member. 10. Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study. Prior to Scheduled Visit, each subject must not have: 1. History of exposure to suspected or confirmed rabid animal. 2. Receipt of rabies immunoglobulins, non-study rabies vaccine following completion of V49_23 study. 3. Hypersensitivity, including allergy, to any component of vaccines, medicinal products or medical equipment whose use is foreseen in this study. 4. Clinical conditions representing a contraindication to intramuscular vaccination and blood draws. 5. Systemic administration of corticosteroids (PO/IV/IM) for more than 14 consecutive days within 90 days prior to informed consent or planning to receive them during the participation to the study. 6. Administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to informed consent or planning to receive them during the participation to the study. 7. Received immunoglobulins or any blood products within 180 days prior to informed consent or planning to receive them during the participation to the study. 8. Study personnel as well as their immediate family or household member. 9. Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study. Prior to booster vaccination, each subject eligible for booster vaccination (i.e., subjects with RVNA concentrations <0.5 IU/mL at the first visit of this extension study [Day 1, Year 3] or at the following year visits [Year 4 to Year 9]) should be in good health status and must not have none of the following: 1. Progressive, unstable or uncontrolled clinical conditions. 2. Abnormal function of the immune system resulting from: 1. Clinical conditions. 2. Systemic administration of corticosteroids (PO/IV/IM) for more than 14 consecutive days within 90 days prior to the Ad hoc visit or receipt or planning to receive them during the participation to the study. 3. Administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to the Ad hoc visit or receipt or planning to receive them during the participation to the study. 3. Receipt of non-study rabies vaccine. 4. Receipt of any other vaccines within 28 days prior to the booster dose or planning to receive any vaccine within 28 days from the booster dose. 5. Receipt of any investigational or non-registered medicinal product within 14 days before booster dose till next Scheduled Clinic Visit after booster dose administration. 6. Receipt of anti-malarial medications within 14 days before booster dose till next Scheduled Clinic Visit after booster dose administration. Prior to receipt of booster study vaccination, subjects must be evaluated to confirm that they are in good health and they are eligible for subsequent vaccination. If subjects meet any of the original exclusion criteria listed above, they should not receive additional vaccinations.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Rabipur
Subjects in all the groups received Rabipur vaccine booster dose, administered intramuscularly in the deltoid region of the non-dominant arm
Procedure:
Blood sampling
Blood samples were drawn from all subjects at day 1 and then at subsequent year intervals from extension study day 1 onwards.

Locations

Country Name City State
Austria GSK Investigational Site Wien
Germany GSK Investigational Site Berlin
Germany GSK Investigational Site Berlin
Germany GSK Investigational Site Hamburg
Germany GSK Investigational Site Muenchen Bayern
Germany GSK Investigational Site Rostock Mecklenburg-Vorpommern
Switzerland GSK Investigational Site Zuerich

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

Austria,  Germany,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of subjects reporting serious adverse events (SAEs) after a booster dose of PCEC (purified chick embryo cell culture) rabies vaccine An SAE is defined as any untoward medical occurrence that at any dose results in one or more of the following:
Death
Is life-threatening
Requires or prolonged hospitalization.
Persistent or significant disability/incapacity
Congenital anomaly/or birth defect.
An important and significant medical event that may not be immediately life threatening or resulting in death or hospitalization but, based upon appropriate medical judgment, may jeopardize the subject or may require intervention to prevent one of the other outcomes listed above.
Safety is assessed as the number of subjects reporting SAEs after a booster dose of PCEC rabies vaccine following a primary series of accelerated or conventional rabies PrEP (pre-exposure) IM (intramuscular) regimen in the parent study V49_23.
From the time of booster dose administration(Day 1 in extension study)until completion of safety follow-up period(day of next Scheduled Clinic Visit after booster dose/on date of Early Termination Visit, whichever is earlier,assessed up to year 10)
Primary Time to first RVNA (Rabies Virus Neutralizing Antibodies) concentrations <0.5 IU/mL. The time until RVNA concentrations drop below 0.5 IU/mL is calculated to compare the long-term persistence of antibody responses in subjects who received a primary series of accelerated or conventional rabies PrEP IM regimen in the parent study V49_23 Throughout the study duration (From 1 year after primary dose schedule in parent study V49_23 to year 10).
Primary RVNA concentrations in terms of Geometric Mean Concentrations (GMCs) 7 days after the booster dose. Antibody concentrations at 7 days after booster dose are measured in terms of GMCs. At 7 days after booster dose
Primary RVNA Geometric Mean Ratios (GMRs) at 7 days after the booster dose vs. antibody concentration before the booster dose. For subjects receiving a booster dose, analysis of boostability is conducted 7 days after administration of the booster dose by providing GMRs and associated CIs, considering the antibody value at the time of booster dose administration as baseline. At 7 days after booster dose versus before booster dose administration (baseline- 6 months before booster dose).
Primary Percentages of subjects with RVNA concentrations = 0.5 IU/mL as measured by RFFIT (Rapid Fluorescent Focus Inhibition Test) analysis at 7 days after booster dose. The percentages of subjects with RVNA concentrations = 0.5 IU/mL are measured at 7 days after booster dose At 7 days after booster dose
Primary Percentages of subjects with RVNA concentrations = 0.5 IU/mL as measured by RFFIT (Rapid Fluorescent Focus Inhibition Test) analysis. The percentages of subjects with RVNA concentrations = 0.5 IU/mL are measured at year 3 after primary series of vaccination. At year 3 after primary series of vaccine administration.
Primary Percentages of subjects with RVNA concentrations = 0.5 IU/mL as measured by RFFIT (Rapid Fluorescent Focus Inhibition Test) analysis. The percentages of subjects with RVNA concentrations = 0.5 IU/mL are measured at year 4 after primary series of vaccination. At year 4 after primary series of vaccine administration.
Primary Percentages of subjects with RVNA concentrations = 0.5 IU/mL as measured by RFFIT (Rapid Fluorescent Focus Inhibition Test) analysis. The percentages of subjects with RVNA concentrations = 0.5 IU/mL are measured at year 5 after primary series of vaccination. At year 5 after primary series of vaccine administration.
Primary Percentages of subjects with RVNA concentrations = 0.5 IU/mL as measured by RFFIT (Rapid Fluorescent Focus Inhibition Test) analysis. The percentages of subjects with RVNA concentrations = 0.5 IU/mL are measured at year 6 after primary series of vaccination. At year 6 after primary series of vaccine administration.
Primary Percentages of subjects with RVNA concentrations = 0.5 IU/mL as measured by RFFIT (Rapid Fluorescent Focus Inhibition Test) analysis. The percentages of subjects with RVNA concentrations = 0.5 IU/mL are measured at year 7 after primary series of vaccination. At year 7 after primary series of vaccine administration.
Primary Percentages of subjects with RVNA concentrations = 0.5 IU/mL as measured by RFFIT (Rapid Fluorescent Focus Inhibition Test) analysis. The percentages of subjects with RVNA concentrations = 0.5 IU/mL are measured at year 8 after primary series of vaccination. At year 8 after primary series of vaccine administration.
Primary Percentages of subjects with RVNA concentrations = 0.5 IU/mL as measured by RFFIT (Rapid Fluorescent Focus Inhibition Test) analysis. The percentages of subjects with RVNA concentrations = 0.5 IU/mL are measured at year 9 after primary series of vaccination. At year 9 after primary series of vaccine administration.
Primary Percentages of subjects with RVNA concentrations = 0.5 IU/mL as measured by RFFIT (Rapid Fluorescent Focus Inhibition Test) analysis. The percentages of subjects with RVNA concentrations = 0.5 IU/mL are measured at year 10 after primary series of vaccination. At year 10 after primary series of vaccine administration.
Secondary RVNA Geometric Mean Concentrations (GMCs) The RVNA GMCs with the 95% CI are calculated at Year 3 after primary series of vaccination At year 3 after primary series of vaccine administration.
Secondary RVNA Geometric Mean Concentrations (GMCs) The RVNA GMCs with the 95% CI are calculated at Year 4 after primary series of vaccination At year 4 after primary series of vaccine administration.
Secondary RVNA Geometric Mean Concentrations (GMCs) The RVNA GMCs with the 95% CI are calculated at Year 5 after primary series of vaccination At year 5 after primary series of vaccine administration.
Secondary RVNA Geometric Mean Concentrations (GMCs) The RVNA GMCs with the 95% CI are calculated at Year 6 after primary series of vaccination At year 6 after primary series of vaccine administration.
Secondary RVNA Geometric Mean Concentrations (GMCs) The RVNA GMCs with the 95% CI are calculated at Year 7 after primary series of vaccination At year 7 after primary series of vaccine administration.
Secondary RVNA Geometric Mean Concentrations (GMCs) The RVNA GMCs with the 95% CI are calculated at Year 8 after primary series of vaccination At year 8 after primary series of vaccine administration.
Secondary RVNA Geometric Mean Concentrations (GMCs) The RVNA GMCs with the 95% CI are calculated at Year 9 after primary series of vaccination At year 9 after primary series of vaccine administration.
Secondary RVNA Geometric Mean Concentrations (GMCs) The RVNA GMCs with the 95% CI are calculated at Year 10 after primary series of vaccination At year 10 after primary series of vaccine administration.
Secondary Reverse Cumulative Distribution Plots (RCDPs) for subjects with RVNA concentrations =0.5 IU/mL. The RCDPs are provided by treatment group, at year 3 At year 3
Secondary RCDPs for subjects with RVNA concentrations =0.5 IU/mL. The RCDPs are provided by treatment group, at year 4 At year 4
Secondary RCDPs for subjects with RVNA concentrations =0.5 IU/mL. The RCDPs are provided by treatment group, at year 5 At year 5
Secondary RCDPs for subjects with RVNA concentrations =0.5 IU/mL. The RCDPs are provided by treatment group, at year 6 At year 6
Secondary RCDPs for subjects with RVNA concentrations =0.5 IU/mL. The RCDPs are provided by treatment group, at year 7 At year 7
Secondary RCDPs for subjects with RVNA concentrations =0.5 IU/mL. The RCDPs are provided by treatment group, at year 8 At year 8
Secondary RCDPs for subjects with RVNA concentrations =0.5 IU/mL. The RCDPs are provided by treatment group, at year 9 At year 9
Secondary RCDPs for subjects with RVNA concentrations =0.5 IU/mL. The RCDPs are provided by treatment group, at year 10 At year 10
See also
  Status Clinical Trial Phase
Completed NCT04074928 - Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects Phase 3
Completed NCT03321968 - Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults Phase 3
Completed NCT04644484 - A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety Phase 3
Completed NCT00984945 - Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults Phase 1
Completed NCT00734175 - Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine Vaccine Phase 1
Completed NCT00516035 - Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy Adults Phase 1
Active, not recruiting NCT05284097 - Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study Phase 2
Completed NCT03739112 - Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly Phase 3
Recruiting NCT06113757 - Investigation of Efficacy and Safety of Electrical Signal Therapy Provided by Dr Biolyse® Device in COVID-19 Disease N/A
Completed NCT01991587 - Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults Phase 1/Phase 2
Completed NCT03294135 - The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine Phase 4
Active, not recruiting NCT05619770 - Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects Phase 1
Not yet recruiting NCT01289301 - Studying the Effect of Changing Immunosuppression in Case of Polyoma BK Virus Infection of the Renal Transplant Phase 4
Active, not recruiting NCT01055990 - Basic and Clinical Research on Applying Blood Fix to Treat Critical H1N1 Patients Phase 2
Completed NCT01842997 - Safety of H1N1 Influenza Vaccination in Pregnant Women Phase 4
Completed NCT00980447 - Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults Phase 2
Completed NCT00380237 - Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study B) Phase 1
Completed NCT00219453 - Pilot Safety Study to Determine the Ability of the Protector Cap Jet Injector to Prevent Cross-Contamination Phase 1
Completed NCT02548078 - A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children Phase 2
Completed NCT01480258 - Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008) Phase 3